




RealRate

# HEALTH SERVICES 2026

Lisata Therapeutics INC  
Rank 36 of 58





RealRate

# HEALTH SERVICES 2026

## Lisata Therapeutics INC Rank 36 of 58



The relative strengths and weaknesses of Lisata Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lisata Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Lisata Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 22% points below the market average of 150%.

Input Variable	Value in 1000 USD
Assets, Current	17,703
Assets, Non-Current	23
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	10,430
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	3,071
Long Term Liabilities	72
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	44
Other Expenses	6,987
Other Liabilities	0
Other Net Income	661
Other Revenues	170
Property Plant and Equipment	18
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	17,744
Liabilities	3,143
Expenses	17,417
Revenues	170
Stockholders Equity	14,601
Net Income	-16,586
Comprehensive Net Income	-16,542
BaseVar	19,590
ECR before LimitedLiability	44%
Economic Capital Ratio	128%